|
Approve Suite Weekly · Tuesday, October 27, 2026 · read online
8-K: Traws Pharma, Inc. mentions clinical hold
Traws Pharma discloses clinical hold risk in Material Adverse Change disclosure. Clinical holds stop ongoing clinical trials and can delay or prevent product development. This SEC disclosure signals investors of regulatory risk but does not confirm an active hold has been imposed. Instrumentation Laboratory recalls HemoslL AcuStar HIT-IgG assay worldwide for calibration and bias issues. This Class I recall of a critical HIT diagnostic test affects assay accuracy with up to 47% negative bias, potentially causing missed or incorrect diagnosis of a serious thrombotic disorder. The worldwide distribution and ongoing status signal broad patient risk and substantial quality system failures in device manufacturing or validation. The pattern? Recalls led the week with 71, ahead of CFR amendments (25), out of 110 counted.
This week's author: Ryan Burke, Approve Suite
8-K: Traws Pharma, Inc. mentions clinical hold
8-K · Traws Pharma, Inc.
Traws Pharma discloses clinical hold risk in Material Adverse Change disclosure.
Why it matters. Clinical holds stop ongoing clinical trials and can delay or prevent product development. This SEC disclosure signals investors of regulatory risk but does not confirm an active hold has been imposed.
What to watch. Items 1.01, 2.02 and 8.01 carry the material terms; the exhibits hold the detail.
READ MORE → · open in Approve Suite
|
Presented by Approve Suite
Put a watchlist on this. Name your CDMO and competitors; get these the day they post. $79/mo, no card to start. See pricing →
|
Class I: Instrumentation Laboratory — HemoslL AcuStar HIT-lgG(PF-4). Part Number: 0009800127. in vitro diagnostic
Class I · Instrumentation Laboratory
Instrumentation Laboratory recalls HemoslL AcuStar HIT-IgG assay worldwide for calibration and bias issues.
Why it matters. This Class I recall of a critical HIT diagnostic test affects assay accuracy with up to 47% negative bias, potentially causing missed or incorrect diagnosis of a serious thrombotic disorder. The worldwide distribution and ongoing status signal broad patient risk and substantial quality system failures in device manufacturing or validation.
What to watch. The classification and, later, the termination notice both post to openFDA; Class I recalls also appear as safety alerts.
READ MORE → · open in Approve Suite
|
Presented by Approve Suite
Put a watchlist on this. Name your CDMO and competitors; get these the day they post. $79/mo, no card to start. See pricing →
|
Regulatory Considerations for Prescription Drug Use-Related Software; Guidance for Industry; Availability
Final guidance
FDA issues final guidance on regulatory treatment of prescription drug use-related software outputs.
Why it matters. This final guidance clarifies how FDA's labeling authorities apply to software outputs disseminated by drug sponsors. It establishes regulatory expectations for prescription drug-related software, affecting how sponsors must design, label, and manage such software products.
What to watch. Final guidance applies on publication. If a draft it replaces was followed, the changed sections are the ones to read.
READ MORE → · open in Approve Suite
By the numbers
Inspections: 0 NAI · 0 VAI · 0 OAI Warning letters: 0 Class I recalls: 4 (Class II 65, Class III 2) Trial stops and status changes: 0 (results posted: 1) Raises: 8, $303M disclosed
235 events, down 59% on the prior 7 days.
205 listed companies report under 12 months of runway.
Signals
1. Class I: Instrumentation Laboratory — HemoslL AcuStar HIT-lgG(PF-4). Part Number: 0009802028. in vitro diagnostic (OUS only) Class I · Instrumentation Laboratory app 2. 8-K: Aclaris Therapeutics, Inc. mentions topline results 8-K · Aclaris Therapeutics, Inc. app 3. 8-K: Acumen Pharmaceuticals, Inc. mentions topline results 8-K · Acumen Pharmaceuticals app 4. Drug shortage current: Clonazepam Tablet (Teva Pharmaceuticals USA, Inc.) Teva Pharmaceuticals USA, Inc app 5. Drug shortage current: Bacitracin Ophthalmic Ointment (Padagis US LLC) Padagis US LLC app 6. Questions and Answers Regarding Mandatory Cosmetics Recalls; Guidance for Industry; Availability Final guidance app
Why this exists
Approve Suite Weekly exists so a QA or RA lead can read one email on Tuesday and know what changed in FDA regulation, inspections and trials in the past week. Every line links to its public source.
Sponsor this email
How was this week's email?
AwesomeDecentNot great
| 